Protein-based COVID-19 Vaccine Found 100% Effective Against Hospitalization

The peer-review journal Vaccine recently announced a post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled clinical trial of Maryland-based Novavax NVX-CoV2373 vaccine efficacy against hospitalization.

Published on April 29, 2023, the Novavax COVID-19 vaccine arm showed no instances of hospitalization among participants in both the per-protocol efficacy analysis and expanded efficacy analysis populations.

As a result, the vaccine demonstrated a 100% efficacy rate against hospitalization in both groups.

Compared to the per-protocol efficacy analysis population of the PREVENT-19 study, the percentage of total participants with any coexisting conditions (47.3%) or with a medical history of obesity (37.2%) was higher among hospitalized participants from the expanded efficacy analysis population (100%, and 91%, respectively), though the latter only represents a small fraction of the former's sample size.

In summary, these researchers wrote, 'These additional data from the PREVENT-19 trial provide relevant public health information concerning the attributes of NVX-CoV2373 (Nuvaxovid™, CovoVax™).'

Disclosures: The authors declare the financial interests/personal relationships that may be considered potential competing interests.

Note: A separate phase 3 randomized clinical trial published in The JAMA Network on April 26, 2023, found Novavax vaccine efficacy was 79.5%, and reactogenicity was mostly mild to moderate and transient; no safety concerns were identified in 2,247 adolescents.